Utama › Kanser Laring › Arizona
Kajian klinikal Kanser Laring di Arizona
5 kajian untuk Kanser Laring sedang mencari peserta di lokasi di Arizona.
Bandar di Arizona
Teks kajian rasmi (Bahasa Inggeris)
Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer
- Banner University Medical Center - Tucson, Tucson
- University of Arizona Cancer Center-North Campus, Tucson
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 29 Sep 2026 · NCT07195734BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
- Mayo Clinic Hospital in Arizona, Phoenix
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT05136196Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
- Cancer Center at Saint Joseph's, Phoenix
- Banner University Medical Center - Tucson, Tucson
- University of Arizona Cancer Center-North Campus, Tucson
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 14 Sep 2026 · NCT02734537Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
- Arizona Center for Cancer Care - Gilbert, Gilbert
- Arizona Center for Cancer Care-Peoria, Peoria
- Arizona Center for Cancer Care - Phoenix, Phoenix
- dan 3 lagi
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 17 Ogo 2026 · NCT06532279SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Scottsdale
Mengambil pesertaKajian pemerhatian
Semua umur · Semua jantina · Dikemas kini 28 Okt 2025 · NCT03452774Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.